Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Crescita Therapeutics Inc T.CTX

Alternate Symbol(s):  CRRTF

Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.


TSX:CTX - Post by User

Bullboard Posts
Comment by TheRock07on Oct 11, 2016 5:24pm
120 Views
Post# 25332611

RE:RE:More ISDIN Products launch in this quarter

RE:RE:More ISDIN Products launch in this quarter I don't think that Pliaglis sales in Mexico and Canada will be that large relative to the US, assuming a modest royalty.
Perhaps another $1 million or so.
But, sales of Intega products in the US, aggressively promoted, could be of the order of $45 million , as previously outlined in a recent post.

Crescita currently trades at just 0.71 of hard book which is less than its cash.

With annual sales in 2017 easily doubling those of 2016, it's a no brainer to add more at these prices.

We have a former President of Valeant who recently joined our BOD , plus our new CEO is a former Valeant employee and we have Sachria who was the CFO  of Paladin and current President of GUD who are now running CTX.

This combo of great management , superb balance sheet and strong growth profile should get us to the $10 mark over the next 12 to 18 months.... based on current peer valuation multiples
Bullboard Posts